Diligence memo · auto-generated · as of July 2, 2026
XRad Therapeutics, Inc.
XRad Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
XRad Therapeutics, Inc. operates in Biotechnology, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
XRad Therapeutics, Inc. has raised $499K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $499K on 2017-12-04.
Most recent recorded round closed around 2017-12-04.
Valuation (modeled)modeled
Provath models XRad Therapeutics, Inc. at approximately $28M (range $266K–$312M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.30× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era. Within the normal band (130% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 10% of Biotechnology peers (4293 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: New Vital Signs, Inc., Cerebral Magnetics INC, NutriBand Inc., Jivana Biotechnology Inc, AnTolRx, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.